Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management
Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies
Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons
Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression
MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission
Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma
Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption
High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors
Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120–CD4-binding site from long-term survivors of HIV infection
Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy
Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers
Keratinization of the adult male foreskin and implications for male circumcision
Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART
The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa
Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience
Factors associated with delayed entry into primary HIV medical care after HIV diagnosis
Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients
Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2
Available evidence does not support serosorting as an HIV risk reduction strategy
Available evidence does not support serosorting as an HIV risk reduction strategy: author's reply
Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection
How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials